Fig. 2From: Dose-escalation by hypofractionated simultaneous integrated boost IMRT in unresectable stage III non-small-cell lung cancerThe median follow-up time was 77.1 (range 4.3–80.6) months. The median progression-free survival (PFS) and overall survival (OS) were 15.4 and 27.3 monthsBack to article page